Follow on Google News News By Tag Industry News * Market research reports * More Industries... News By Place Country(s) Industry News
Follow on Google News | OTC Healthcare in the United StatesOTC Healthcare in the United States report offers a comprehensive guide to the size and shape of the market at a national level.
By: Bharat Book Bureau Why buy this report Get insight into trends in market performance Pinpoint growth sectors and identify factors driving change Identify market and brand leaders and understand the competitive environment Product coverage Adult mouthcare; Allergy care; Analgesics; Calming and sleeping products; Child-specific OTC healthcare; Cough; cold and allergy (hay fever) remedies; Digestive remedies; Ear care; Emergency contraception; Executive summary 1. EXECUTIVE SUMMARY Steady growth in OTC sales US sales of OTC healthcare products continued to grow at a steady pace in 2005. Vitamin E, ketoprofen and naproxen all suffered sales losses due to renewed concerns about the safety of these products stemming from recently published research and lawsuits over prescription non-steroidal anti-inflammatory drugs (NSAIDs) like Vioxx. The absence of new product innovations led to flat sales for some mature categories like adult mouthcare, calming and sleeping products, and wound treatments. Sales of digestive remedies, cough, cold and flu remedies, medicated skin care and dietary supplements continued to show strong growth in 2005 though, and made up for the negative effect of losses from these other products. Market exits as companies focus on Rx business The US OTC healthcare market was a changing landscape in 2005 as Bristol-Myers Squibb and Boots International both decided to exit in order to focus on their prescription drug businesses. Bristol-Myers Squibb sold its US and Canadian consumer health portfolio, including rights to the Excedrin, Vagistat and Comtrex brands, to Novartis. Boots International announced the sale of its US OTC healthcare business to Reckitt Benckiser. The deal includes the Clearasil, Nurofen and Strepsils brands. Wyeth also sold its Solgar Vitamin and Herb division to NBTY during 2005. Finally, Pfizer has announced its intention to sell its consumer healthcare division, a move that promises to impact the US OTC healthcare market even more in 2006. These market exits signal a greater trend for pharmaceutical companies to focus on the more profitable prescription drug market at the expense of OTC healthcare innovations, and such transitions of ownership have slowed the pace of new product development and overall growth in OTC healthcare sales. OTC healthcare switches on the horizon Recent years saw a slower pace of US Food and Drug Administration (FDA) approvals for OTC healthcare switches. The only significant new approval in 2005 was for Zantac 150mg, a higher dose version of the popular Zantac 75mg H2 blocker. In a highly politically charged move, the FDA also postponed OTC approval for Barr Pharmaceutical's morning after contraceptive pill in late 2005, despite years of testing and effective prescription use, and the recommendation for approval by the FDA's own panel. Nevertheless, FDA approvals of the morning after pill, cholesterol- Foremost among these is GlaxoSmithKline's orlistat drug Xenical. The weight-loss medication won initial approval from the FDA for OTC sale under the brand Alli in January 2006, and will most likely be brought to market sometime during 2006. Alli would be the first OTC obesity pill approved in the US, and promises to be very popular due to the ever increasing obese population, despite lingering questions over its efficacy. For more information, Please visit : http://www.bharatbook.com/ Website: www.bharatbook.com End
|
| |||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number